340B Manufacturer Exclusions Summary

Updated May 23, 2023

Manufacturer	Effective Date	CEs Affected	ESP Submissions
Eli Lilly	9/1/2020	All	Yes
AstraZeneca	10/1/2020	All	No
Novartis	11/16/2020	Hospitals Only	Yes
Novo Nordisk	1/1/2021	Hospitals Only	Yes
Sanofi	3/1/2021	Hospitals and CHC	Yes – but HOSPITALS can only pick 1 contract pharmacy starting 6/1/2023
Boehringer Ingelheim	8/1/2021	Hospitals and CHC	No
Merck	9/1/2021	Hospitals and CHC	Yes – but can only pick 1 contract pharmacy starting 6/12/2023
United Therapeutics	12/1/2021	All	Yes
UCB	12/31/2021	Hospitals Only	No
Amgen	1/3/2022	Hospitals Only	Yes – but can only pick 1 contract pharmacy starting 4/11/2023
Abbvie	2/1/2022	Hospitals Only	Yes
Bristol Myers Squibb	3/1/2022	All	No
Pfizer	3/1/2022	Hospitals Only	Yes – but can only pick 1 contract pharmacy starting 5/1/2023 specifically for Xeljanz
GlaxoSmithKline	4/1/2022	Hospitals Only	Yes
Janssen	5/2/2022	Hospital Only	Yes – but can only pick 1 contract pharmacy starting 3/7/2023
Gilead	5/2/2022	All	Yes
Exelixis	7/6/2022	Hospitals Only	Yes – but can only pick 1 contract pharmacy starting 5/15/2023
Bausch Health	8/1/2022	All	Yes
Biogen	2/1/2023	Hospitals Only	No
Bayer Health	3/1/2023	Hospital Only	Yes – but can only pick 1 contract pharmacy starting 6/1/2023
EMD Serono	3/1/2023	Hospitals Only	Yes